The Clinical Core will support projects and cores in areas relevant to clinical research. The three major components to the core include clinical trials, the prostate cancer clinical research information system, and advocacy activities.
Specific Aim 1 : To design, execute, accrue to, or otherwise facilitate the conduct and timely completion of clinical trials relevant to SPORE projects or Cores. UW, UBC, and OHSU clinical investigators will participate in this aspect of the core. Clinical trials specific to projects include pre- and post-radiation biopsy (Project 2), neoadjuvant IMC-A12 (Project 4), and MAXTAP (Project 5) studies. Numerous SPORE related trials, including InterSPORE trials, are in progress or in planning.
Specific Aim 2 : To continue to develop and enhance Caisis, the prostate cancer clinical research information system. Development of clinic abstraction templates, biospecimen clinical annotation protocol, quality control and assurance procedures, patient consent and specimen acquisition processes, and specimen tracking are priorities.
Specific Aim 3 : To support and engage the SPORE Advocacy Committee in the activities of the SPORE as well as in their own mission as a group. Goals of the committee include: continued interaction with local support groups, involvement of minority members on the committee and in clinical trials, invitation of UBC and OHSU patients to join Advocacy Committee. In order to better understand and interact with the SPORE projects, each Advocate will focus on a single project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097186-10
Application #
8330647
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2013-08-31
Budget Start
2011-09-08
Budget End
2012-08-31
Support Year
10
Fiscal Year
2011
Total Cost
$159,855
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Levesque, Christine; Nelson, Peter S (2018) Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. Cold Spring Harb Perspect Med 8:
Barnard, Monique; Quanson, Jonathan L; Mostaghel, Elahe et al. (2018) 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer. J Steroid Biochem Mol Biol 183:192-201
Ganaie, Arsheed A; Beigh, Firdous H; Astone, Matteo et al. (2018) BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models. Clin Cancer Res 24:6421-6432
Schweizer, Michael T; Haugk, Kathleen; McKiernan, Jožefa S et al. (2018) A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS One 13:e0198389
Peacock, James W; Takeuchi, Ario; Hayashi, Norihiro et al. (2018) SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol Med 10:219-238
Pollan, Sara G; Huang, Fangjin; Sperger, Jamie M et al. (2018) Regulation of inside-out ?1-integrin activation by CDCP1. Oncogene 37:2817-2836
Wu, Yi-Mi; Cie?lik, Marcin; Lonigro, Robert J et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173:1770-1782.e14
Schweizer, Michael T; Hancock, Michael L; Getzenberg, Robert H et al. (2018) Hormone levels following surgical and medical castration: defining optimal androgen suppression. Asian J Androl 20:405-406
Yan, Qingxiang; Bantis, Leonidas E; Stanford, Janet L et al. (2018) Combining multiple biomarkers linearly to maximize the partial area under the ROC curve. Stat Med 37:627-642

Showing the most recent 10 out of 400 publications